Guggenheim lowered the firm’s price target on Zentalis (ZNTL) to $6 from $8 and keeps a Buy rating on the shares after the company provided a comprehensive azenosertib update. Taken together, the firm believes the data show “clear” and consistent monotherapy clinical efficacy in Cyclin-E1-positive prOC patients across all three trials that “exceeds the regulatory bar for accelerated approval in a relatively large dataset,” the analyst tells investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis price target lowered to $6 from $8 at Wells Fargo
- Zentalis price target lowered to $10 from $20 at H.C. Wainwright
- Zentalis price target lowered to $10 from $20 at Oppenheimer
- Zentalis Pharmaceuticals Announces New Study for Azenosertib
- Zentalis presents updated clinical data on azenosertib